2 active not recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Edodekin alfa: new trials by email Literature Review of Edodekin alfa trials Research Report on Edodekin alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 36 | 2018-05-30 | 2026-07-31 |
| Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery Cetuximab, Edodekin alfa, Laboratory Biomarker Analysis - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 23 | 2011-10-26 | 2026-07-29 |
Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1)
National Cancer Institute (NCI) (2)
United States (2)
Diwakar Davar (1) · William E Carson (1)
N01CM00070 (1), P30CA016058 (1), U01CA076576 (1), UM1CA186690 (1), UM1CA186712 (1)